Compare VVOS & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | ONCO |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 3.0M |
| IPO Year | 2020 | 2021 |
| Metric | VVOS | ONCO |
|---|---|---|
| Price | $0.14 | $0.43 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.12 | N/A |
| AVG Volume (30 Days) | 2.2M | ★ 6.4M |
| Earning Date | 11-18-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.76 | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,443,000.00 | $815,371.00 |
| Revenue This Year | $24.92 | N/A |
| Revenue Next Year | $56.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $0.12 | $0.09 |
| 52 Week High | $3.09 | $798.00 |
| Indicator | VVOS | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 33.63 |
| Support Level | $0.13 | $0.09 |
| Resistance Level | $0.55 | $1.02 |
| Average True Range (ATR) | 0.01 | 0.07 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 25.35 | 10.92 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.